Arcus Biosciences (RCUS) PT Raised to $46 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS)
October 24, 2024 1:48 PM EDTBofA Securities analyst Jason Zemansky reiterated a Neutral rating and $22.00 price target on Arcus Biosciences (NYSE: RCUS).
The analyst comments "Arcus Q&A investor follow-up to this mornings presentation of the ARC-20 casdatifan (cas) at ENA didnt offer much in the way of new insights, in... More
